Table 4.
Hazard radios for in-field control (IFC), progression-free survival (PFS), and overall (OS) rates
| Covariate | P in univariate analysis | P in multivariate analysis | Hazard ratio (95% CI) | |||
|---|---|---|---|---|---|---|
| In-field control rate | 2-year IFC (%) | |||||
| Age | <67 vs ≥67 | 78.6 | 71.7 | 0.339 | ||
| Sex | Male vs female | 72.6 | 91.7 | 0.165 | ||
| T-category | T1/2 vs 3/4 | 84.6 | 59.2 | 0.004* | 0.167 | 0.482 (0.171–1.356) |
| N-category | 0/1 vs 2/3 | 77.1 | 71.4 | 0.602 | ||
| Stage | 1/2 vs 3/4 | 86.7 | 67.4 | 0.020* | 0.524 | 0.632 (0.154–2.594) |
| NAC | Yes vs no | 59.5 | 77.2 | 0.258 | ||
| RT technique | IMRT vs non-IMRT | 68.4 | 88.2 | 0.050* | 0.663 | 0.622 (0.073–5.281) |
| Systemic therapy | Yes vs no | 67.7 | 84.0 | 0.055 | ||
| Stage III/IV yes (n = 32) vs no (n = 6) | 65.7 | 77.8 | 0.633 | |||
| RT total dose | <70 Gy vs ≥70 Gy | 95.0 | 70.1 | 0.033* | ||
| p53 | Mutated vs un-mutated | 72.6 | 79.2 | 0.357 | ||
| p16 | HPV infected vs un-infected pattern | 76.7 | 74.0 | 0.360 | ||
| BerEP4 | Intense vs non-intense expression | 52.2 | 84.0 | 0.001* | 0.009* | 3.069 (1.328–7.092) |
| Progression-free survival rate | 2-year PFS (%) | |||||
| Age | <67 vs ≥67 | 59.8 | 61.6 | 0.983 | ||
| Sex | Male vs female | 58.2 | 75.0 | 0.316 | ||
| T-category | T1/2 vs 3/4 | 66.4 | 50.4 | 0.134 | ||
| N-category | 0/1 vs 2/3 | 67.2 | 49.9 | 0.136 | ||
| Stage | 1/2 vs 3/4 | 71.0 | 54.2 | 0.082 | 0.111 | 0.566 (0.281–1.139) |
| NAC | Yes vs no | 42.9 | 63.0 | 0.317 | ||
| RT technique | IMRT vs non-IMRT | 54.9 | 72.4 | 0.168 | ||
| Systemic therapy | Yes vs no | 58.6 | 63.7 | 0.659 | ||
| Stage III/IV yes (n = 32) vs no (n = 6) | 50.8 | 50.0 | 0.629 | |||
| RT total dose | <70 Gy vs ≥70 Gy | 77.4 | 55.6 | 0.100 | ||
| p53 | Mutated vs un-mutated | 57.3 | 66.5 | 0.297 | ||
| p16 | HPV infected vs un-infected pattern | 58.3 | 60.7 | 0.789 | ||
| BerEP4 | Intense vs non-intene expression | 42.6 | 67.8 | 0.025* | 0.037* | 1.976 (1.040–3.755) |
| Overall survival rate | 2-year OS (%) | |||||
| Age | <67 vs ≥67 | 80.0 | 81.9 | 0.968 | ||
| Sex | Male vs female | 80.4 | 83.3 | 0.725 | ||
| T-category | T1/2 vs 3/4 | 90.1 | 65.6 | 0.021* | 0.547 | 0.850 (0.502–1.441) |
| N-category | 0/1 vs 2/3 | 86.3 | 71.2 | 0.061 | ||
| Stage | 1/2 vs 3/4 | 95.0 | 71.7 | 0.017* | 0.141 | 0.341 (0.081–1.428) |
| NAC | Yes vs no | 68.8 | 82.7 | 0.356 | ||
| RT technique | IMRT vs non-IMRT | 76.5 | 89.2 | 0.188 | ||
| Systemic therapy | Yes vs no | 74.4 | 88.9 | 0.176 | ||
| Stage III/IV yes (n = 32) vs no (n = 6) | 72.8 | 66.7 | 0.546 | |||
| RT total dose | <70 Gy vs ≥70 Gy | 94.7 | 77.3 | 0.078 | ||
| p53 | Mutated vs un-mutated | 76.4 | 90.2 | 0.081 | ||
| p16 | HPV infected vs un-infected pattern | 79.7 | 81.5 | 0.695 | ||
| BerEP4 | Intense vs non-intense expression | 62.2 | 87.9 | 0.011* | 0.036* | 2.597 (1.064–6.335) |
NAC = neoadjuvant chemotherapy, RT = radiation therapy, IMRT = intensity modulated radiation therapy, HPV = human papillomavirus.The p values which are statistically significant are marked with asterisks.